Colinz Laboratories , a pharmaceutical company, has announced significant changes to its board of directors and committee structure, following the passing of a key board member.

Board Changes

The company reported the sad demise of Dr. Mani L.S., who served as a Non-Executive Director. The board expressed deep condolences, acknowledging Dr. Mani's visionary leadership, unwavering commitment, and exemplary guidance that left an indelible mark on the company.

In light of this loss, Colinz Laboratories has appointed Mrs. Vijaya Mani as an Additional Non-Executive Director, effective November 11, 2025. This appointment is subject to shareholder approval at the forthcoming Annual General Meeting.

New Director Profile

Mrs. Vijaya Mani brings a diverse background to the board:

• Educational Background: BA Graduate
• Experience: Extensive experience in Admin and Banking
• Industry Knowledge: Well-versed with pharmaceutical background

The company believes Mrs. Mani's expertise will contribute to its growth and future success.

Committee Restructuring

Following these changes, Colinz Laboratories has reconstituted its board committees. The new structure is as follows:

Regulatory Compliance

Colinz Laboratories has confirmed that Mrs. Vijaya Mani has not been debarred from holding the office of director by any SEBI order or any other authority. This appointment and the subsequent committee restructuring comply with the relevant SEBI regulations and the Companies Act, 2013.

The company's board meeting, where these decisions were made, commenced at 03:30 p.m. and concluded at 5:00 p.m. on November 11, 2025.

These changes mark a significant transition for Colinz Laboratories as it adapts its leadership structure to navigate future challenges and opportunities in the pharmaceutical industry.

Colinz Laboratories Limited announced the passing of its Founder Director, Dr. Mani L.S., on November 7, 2025. Dr. Mani, who served as the Company Secretary and Compliance Officer, was described as a guiding force and principal architect behind the company's vision and values.

Key Details of the Announcement

Dr. Mani L.S. held the position of Director (non-Executive) and was a member of all Board Committees. His roles and committee memberships ceased effective November 7, 2025.

Company's Response and Next Steps

Colinz Laboratories expressed deep sorrow over the loss, acknowledging Dr. Mani's significant contributions to the company. The Board of Directors and employees conveyed their condolences to his family.

In light of this development, the company has outlined the following actions:

1. Immediate Measures: Colinz is taking steps to identify and appoint a qualified Company Secretary to fill the vacancy of Compliance Officer.

2. Interim Arrangement: Mr. Ganesh Chitte, the Chief Financial Officer, will oversee compliance and regulatory functions to ensure continued adherence to all applicable requirements.

The company has informed the Bombay Stock Exchange of these changes, as per regulatory requirements.

About Colinz Laboratories Limited

Colinz Laboratories Limited is identified by the ISIN code INE923C01011. The company's corporate office is located in Mumbai, indicating its presence in the Indian pharmaceutical or laboratory sector.

This announcement marks a significant transition for Colinz Laboratories, as it navigates the loss of a key founding member while ensuring continuity in its operations and compliance functions.